预约演示
更新于：2026-10-15
Dexketoprofen Trometamol
右酮洛芬氨丁三醇
更新于：2026-10-15
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-NSHDSACASA-N |
CAS号22161-81-5 |
关联
93
项与 右酮洛芬氨丁三醇 相关的临床试验CTIS2025-524061-24-01
Study to compare drug availability in the bloodstream of two oral formulations of dexketoprofen in healthy volunteers under fasting conditions.
CTR20250538
一项多中心、随机、双盲、安慰剂平行对照设计，评价右酮洛芬氨丁三醇注射液治疗术后中至重度疼痛的安全性和有效性研究
NCT06878014
Comparison of Safety Profile and Efficacy of Different Doses of Intrathecal Morphine in Total Hip Replacement.
100 项与 右酮洛芬氨丁三醇 相关的临床结果
登录后查看更多信息
100 项与 右酮洛芬氨丁三醇 相关的转化医学
登录后查看更多信息
100 项与 右酮洛芬氨丁三醇 相关的专利（医药）
登录后查看更多信息
1,126
项与 右酮洛芬氨丁三醇 相关的文献（医药）2026-10-06Cureus Journal of Medical Science
Efficacy and Safety of Opioid Analgesia in Acute Abdominal Presentations: A Systematic Review
Review
作者: Payne, Connor A ; Neupane, Ganesh Prasad
Acute abdominal pain is a common emergency department presentation and is often associated with diagnostic uncertainty. Historically, opioid analgesia was used cautiously because of concern that it could alter physical examination findings and interfere with diagnostic accuracy. Non-opioid and opioid-sparing strategies are increasingly used for pain management. This systematic review evaluates the efficacy and safety of analgesic strategies for acute, non-traumatic abdominal pain, with attention to pain relief, adverse effects, rescue analgesia, and diagnostic accuracy. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for randomized comparative trials of opioid-containing treatment versus non-opioid, opioid-sparing, or placebo strategies. Eligible studies included adults aged 18 years or older with acute abdominal pain or an acute intra-abdominal cause of pain; studies limited to renal or ureteric colic were excluded. Of the 316 records identified, 45 duplicates were removed, 271 records were screened, 26 reports underwent full-text assessment, and 16 randomized trials were included. Across the included trials, opioids provided effective short-term analgesia but were not consistently superior to alternatives. Hydromorphone produced greater pain improvement than intravenous lidocaine at 90 minutes (between-group difference = 1.2 points, 95% confidence interval (CI) = 0.3-2.2) with less rescue analgesia. In acute pancreatitis, median Visual Analog Scale (VAS) reductions at 30 minutes were 45.5 (95% CI = 30-54) with tramadol, 41.5 (95% CI = 34-50) with paracetamol, and 40.5 (95% CI = 30-47) with dexketoprofen, with no statistically significant between-group difference. An erector spinae plane block produced lower pain scores and reduced rescue fentanyl compared with intravenous tramadol. In biliary colic, mean pain relief at 30 minutes was 3.8 (95% CI = 2.4-5.2) with ketorolac and 3.9 (95% CI = 2.4-5.3) with meperidine, with no statistically significant between-group difference. Butorphanol provided greater early pain relief than ketorolac at 15 minutes but not at 30 minutes. Low-dose morphine plus paracetamol did not significantly differ from standard-dose morphine, and intravenous lidocaine and morphine did not significantly differ at the primary 60-minute endpoint. Several placebo-controlled trials assessed diagnostic accuracy using different definitions and patient populations. In one trial, diagnostic accuracy was 86% with morphine and 85% with placebo (difference 1 percentage point, 95% CI = -11 to 12). This imprecise estimate does not rule out a clinically important difference, and the available trials do not establish whether opioids affect diagnostic accuracy across acute abdominal presentations. Some studies identified changes in tenderness, rigidity, or localization after analgesia, but these were not consistently associated with diagnostic error or adverse management outcomes. Adverse effects were generally short-term and included nausea, vomiting, dizziness, and sedation, although most trials were not large enough or followed long enough to reliably evaluate uncommon serious adverse events. Overall, the evidence supports an individualized approach to analgesia. Opioids remain effective when clinically indicated, but are not consistently superior to non-opioid or opioid-sparing alternatives, and analgesia should not be routinely delayed solely because of concern for diagnostic interference.
2026-10-01CHIRALITY
Stereoselective Differences in the Percutaneous Permeation of Ketoprofen Enantiomers and the Underlying Chiral Recognition Mechanisms
Article
作者: Dong, Wenxiu ; Meng, Kaile ; Wang, Honghui ; Sun, Yinghua ; Zhou, Zixi ; He, Zhonggui
ABSTRACT:
This research aims to investigate the stereoselective permeation differences and molecular recognition mechanisms of ketoprofen enantiomers in the chiral microenvironment of the stratum corneum (SC). This also aims to provide theoretical support for developing highly efficient and precise single‐enantiomer transdermal drug delivery systems. The permeation behaviors of dexketoprofen and its racemate through excised full‐thickness rat skin in three different solvent systems were studied using Franz diffusion cells. The solubility, apparent partition coefficients, and differential scanning calorimetry were used to assess the physicochemical and thermodynamic properties of both forms. Fourier transform infrared (FTIR),
13
C NMR, attenuated total reflection‐FTIR (ATR‐FTIR), and Raman spectroscopic techniques were extensively performed to investigate micro‐interactions between drug and core SC (ceramide NP and keratin) components. In addition, in order to affirm the mechanisms, binding energy, cohesive energy density, and the radial distribution function along with mean square displacement were evaluated using molecular docking and molecular dynamics simulations. Based on in vitro permeation results, the cumulative permeated amounts of dexketoprofen in all three solvent systems were significantly higher than those of racemic ketoprofen (approximately 1.2‐fold). Characterizations by thermodynamic and physicochemical methods showed that dexketoprofen displayed a relatively low melting point (76.26°C), enthalpy of fusion (26.39 kJ/mol), lattice energy, and higher lipophilicity and solubility, which gave rise to a greater thermodynamic driving force for drug release. Both spectroscopic analyses and molecular simulations confirmed that dexketoprofen formed a stronger intermolecular hydrogen bonding network with ceramide NP (binding energy: −21.63 kcal/mol). This robust spatial affinity remarkably perturbed the tightly ordered arrangement of the SC lipid bilayer, which may induce a decrease in lipid orderliness and substantially increase the fluidity. The transdermal superiority of dexketoprofen within the chiral skin barrier is synergistically attributed to its high thermodynamic activity, driven by a lower lattice energy, and its stronger microscopic stereoselective interactions with SC components. This study systematically elucidates the stereoselective mechanisms underlying the transdermal permeation of chiral drugs, thereby providing a scientific basis for the development of transdermal formulations containing a single enantiomer.
2026-08-01Birth Defects Research
Intentional Dexketoprofen Overdose During Pregnancy: Maternal and Fetal Outcomes in Three Cases
Article
作者: Gungor, Mesut ; Karadas, Baris ; Kaplan, Yusuf Cem ; Yilmaz, Ismail ; Uysal, Nusret
ABSTRACT:
Background:
Dexketoprofen trometamol is a widely used short‐acting nonsteroidal anti‐inflammatory drug. Despite its widespread clinical use, pregnancy‐specific safety data for dexketoprofen as an individual agent are lacking, and no previous report has described maternal or fetal outcomes following overdose in pregnant women.
Cases:
We present three cases of intentional dexketoprofen overdose during pregnancy. Case 1 involved a 33‐year‐old woman at 8 weeks of gestation who ingested dexketoprofen with ibuprofen, pseudoephedrine, and cefuroxime; she delivered a healthy male infant at 37 weeks with no congenital anomalies on follow‐up. Case 2 involved a 36‐year‐old woman at 17 weeks who ingested dexketoprofen with ergotamine tartrate, mecloxamine, caffeine, and paracetamol; she experienced a spontaneous abortion at 20 weeks, complicated by cyst rupture requiring hysterectomy. Case 3 involved a 29‐year‐old woman at 6 weeks who ingested dexketoprofen, paracetamol, and chlorpheniramine, and underwent elective termination at 10 weeks.
Conclusions:
The three cases demonstrated heterogeneous pregnancy outcomes. No congenital anomalies were identified in the single evaluable live‐born infant. Multiple co‐ingested agents substantially complicate causal attribution, most notably ergotamine tartrate in Case 2. The limited case number and outcome heterogeneity preclude identification of a consistent pattern of fetal adverse effects or definitive conclusions regarding fetal risk. All overdoses were intentional, underscoring the importance of integrating psychiatric assessment into toxicological management during pregnancy. These cases represent the first available observational data on maternal and fetal outcomes following intentional dexketoprofen overdose in pregnancy, highlighting the need for a multidisciplinary approach in this clinical setting.
100 项与 右酮洛芬氨丁三醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性腰痛 | 韩国 | 2007-06-12 | |
| 术后疼痛 | 韩国 | 2007-06-12 | |
| 偏头痛 | 中国 | 2006-10-27 | |
| 疼痛 | 中国 | 2006-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 绞痛 | 临床3期 | 中国 | 2018-12-27 | |
| 腰痛 | 临床3期 | 中国 | 2018-12-27 | |
| 急性疼痛 | 临床3期 | 西班牙 | 2016-04-12 | |
| 镇痛 | 临床3期 | 中国 | 2015-10-16 | |
| 中度疼痛 | 临床3期 | 中国 | 2015-10-16 | |
| 重度疼痛 | 临床3期 | 中国 | 2015-10-16 | |
| 背痛 | 临床3期 | 中国 | 2015-07-15 | |
| 肾绞痛 | 临床3期 | 中国 | 2015-07-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | Dexketoprofen chronotherapy | 構蓋膚簾襯鬱鏇顧衊繭(範淵糧顧齋製觸糧衊鑰) = 鏇網築簾繭構鬱壓廠鬱 齋衊鏇範艱積選獵蓋鑰 (積壓鬱淵淵齋鏇鹽獵網 ) 更多 | 积极 | 2026-02-01 | ||
Dexketoprofen control therapy | 構蓋膚簾襯鬱鏇顧衊繭(範淵糧顧齋製觸糧衊鑰) = 夢繭鹹顧餘襯鬱選廠夢 齋衊鏇範艱積選獵蓋鑰 (積壓鬱淵淵齋鏇鹽獵網 ) 更多 | ||||||
临床3期 | - | - | Dexketoprofen 25 mg/Vitamin B (Thiamine 100 mg, Pyridoxine 50 mg, Cyanocobalamin 0.50 mg) FDC | 積構夢齋窪淵襯簾鹹選(膚鹽顧夢獵構獵築膚壓) = 鏇製鑰鏇顧淵構選願選 蓋鬱膚艱顧積齋構遞構 (餘製蓋衊鏇憲製簾膚網, 2.5 ~ 10.5) | 积极 | 2024-06-01 | |
積構夢齋窪淵襯簾鹹選(膚鹽顧夢獵構獵築膚壓) = 顧願醖簾餘糧淵鹹選襯 蓋鬱膚艱顧積齋構遞構 (餘製蓋衊鏇憲製簾膚網, 5.0 ~ 13.8) | |||||||
临床3期 | 641 | 蓋淵窪糧獵夢憲積製衊(醖鏇醖觸繭壓簾繭觸積): P-Value = 0.019 | 积极 | 2016-02-01 | |||
临床4期 | 224 | (Dexketoprofen) | 淵製願窪壓餘繭壓範夢(鑰觸醖淵壓願選觸醖獵) = 獵築衊蓋淵襯鬱獵衊鏇 壓膚鬱顧膚廠鏇願簾廠 (構鹽窪醖簾構網繭糧蓋, 艱膚觸廠築鹽窪鏇憲積 ~ 製鑰廠窪繭鹹簾廠齋鬱) 更多 | - | 2015-07-23 | ||
(Normal Slaline) | 淵製願窪壓餘繭壓範夢(鑰觸醖淵壓願選觸醖獵) = 鹽蓋窪壓夢衊壓淵憲夢 壓膚鬱顧膚廠鏇願簾廠 (構鹽窪醖簾構網繭糧蓋, 膚顧餘衊蓋網築鬱壓獵 ~ 鹹遞觸觸繭餘築鑰願夢) 更多 | ||||||
临床1期 | 26 | (Enantyum® Oral Solution) | 鹹構壓衊艱積獵艱衊廠(顧窪構網憲襯構糧積窪) = 選鬱選積餘繭積襯構淵 醖鹽積鹽壓艱夢壓願淵 (鬱鏇艱鏇範願觸鹹窪淵, 遞獵鑰網願鑰製餘願壓 ~ 選遞艱窪憲構簾選遞憲) 更多 | - | 2015-07-09 | ||
(Keral® Tablet) | 鹹構壓衊艱積獵艱衊廠(顧窪構網憲襯構糧積窪) = 鬱選鹹襯獵製簾簾獵蓋 醖鹽積鹽壓艱夢壓願淵 (鬱鏇艱鏇範願觸鹹窪淵, 窪鏇鏇製積壓繭衊繭鹹 ~ 範壓獵窪鑰廠選憲鬱齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用